Revolution Medicines, Inc.

RVMD · NasdaqGS

Price$0.00+0.00 (+0.00%)

Price History

Volume & Moving Averages

Price50D200D

Analyst Price Target

$0.00▲ 0.0% above current price

Range: $0.00 – $0.00 · 0 analysts

Based on Wall Street analyst estimates — not a Stockinder prediction.

About the company

Jarvis is thinking

Key Metrics

Report card

Open as standalone page ↗

Jarvis is thinking

Recent Notable Coverage

Jarvis is thinking

Report Card

–

Growth

Health

Risk

–

Value

Quality

Ownership

Insider and institutional holdings, from Yahoo Finance — for Indian companies this roughly tracks promoter (insiders) and combined FII/DII (institutions) stakes, though not split out the same way a shareholding-pattern filing would.

Insiders1.9%

Institutions101.1%

Public / Other

Income Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Total money the company brought in from its core business during the period, before any costs are subtracted.	$0	$0	$35.38M	$29.39M	$42.98M
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$1.18B	-$689.52M	-$258.28M	-$188.01M	-$110.70M
Operating income as a percentage of revenue.	–	–	-730.0%	-639.7%	-257.5%
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$1.13B	-$600.09M	-$248.71M	-$187.09M	-$108.16M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-5.95	$-3.58	$-3.08	$-2.57	$-2.01
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-5.95	$-3.58	$-3.08	–	–

Balance Sheet

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$383.75M	$543.06M	$161.41M	$108.50M	$104.27M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$2.35B	$2.56B	$811.93M	$737.99M	$567.40M
Everything the company owes — debt, unpaid bills, and other obligations.	$723.21M	$293.10M	$126.74M	$135.42M	$92.72M
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$1.63B	$2.27B	$685.19M	$602.57M	$474.68M

Cash Flow Statement

	2025-12-31	2024-12-31	2022-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$897.74M	-$557.44M	-$224.40M	-$147.18M	-$100.06M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$15.99M	$10.31M	$10.82M	$6.53M	$2.93M
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$913.73M	-$567.74M	-$235.22M	-$153.71M	-$103.00M

	You	Peer avg
P/E	–	25.4
Revenue Growth	–	+11.2%
ROE	-79.1%	-3.0%

Revolution Medicines, Inc.

Price History

Volume & Moving Averages

Analyst Price Target

About the company

Key Metrics

Report card

Jarvis Analysis

Recent Notable Coverage

Report Card

Ownership

Quick Actions

Reports & Coverage

Con Call Reports

Board of Directors / Annual Reports

Recent Articles

Income Statement

Balance Sheet

Cash Flow Statement

Peer Comparison